Dehydroepiandrosterone Effects on HIV-1 Replication

This study's purpose is to learn how dehydroepiandrosterone (DHEA) affects the HIV virus, the immune system, hormone levels, body composition and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Community Consortium

San Francisco, California, 94110, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Evidence of HIV-1 infection
HIV RNA <50 copies/mL
Stable antiretroviral treatment regimen for at least 8 weeks
Age 18 years or older
Normal pap smear and mammograph within 1 year (females)
Normal prostate-specific antigen level with in one year, age adjusted (males)

Exclusion criteria

Active opportunistic infections or malignancy other than localized cutaneous KS lesions
Concurrent or prior use within the past 8 weeks of DHA, testosterone, other anabolic steroids, corticosteroids, megestrol acetate, growth hormone, IL-2, or thalidomide
Diagnosis of AIDS Dementia Complex (stage II or higher)
Active substance abuse (e.g., alcohol or injection drugs)
Evidence of severe liver dysfunction or hepatic transaminases greater than 3x the upper normal limit
Pregnant or breast-feeding
History of endocrinologically-responsive tumors (e.g., breast, ovarian, uterine, or prostatic cancer, or malignant melanoma)

Treatment and study plan

DHEA

Drug

Sponsors and collaborators

Lead sponsor

National Center for Complementary and Integrative Health (NCCIH)

Nih

Registry information

Important dates

Study start: 2000
Study completion: 2003
First posted: Jul 18, 2003
Registry last updated: Aug 18, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed